These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36525658)

  • 1. A kidney diagnostic's impact on physician decision-making in diabetic kidney disease.
    Datar M; Ramakrishnan S; Chong J; Montgomery E; Goss TF; Coca SG; Vassalotti JA
    Am J Manag Care; 2022 Dec; 28(12):654-661. PubMed ID: 36525658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real World Evidence and Clinical Utility of KidneyIntelX on Patients With Early-Stage Diabetic Kidney Disease: Interim Results on Decision Impact and Outcomes.
    Tokita J; Vega A; Sinfield C; Naik N; Rathi S; Martin S; Wang S; Amoruso L; Zabetian A; Coca SG; Nadkarni GN; Fleming F; Donovan MJ; Fields R
    J Prim Care Community Health; 2022; 13():21501319221138196. PubMed ID: 36404761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
    Lam D; Nadkarni GN; Mosoyan G; Neal B; Mahaffey KW; Rosenthal N; Hansen MK; Heerspink HJL; Fleming F; Coca SG
    Am J Nephrol; 2022; 53(1):21-31. PubMed ID: 35016188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis.
    Fusfeld L; Murphy JT; Yoon Y; Kam LY; Peters KE; Lin Tan P; Shanik M; Turchin A
    PLoS One; 2022; 17(8):e0271740. PubMed ID: 35913946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Real-World Precision Medicine Program Including the KidneyIntelX Test Effectively Changes Management Decisions and Outcomes for Patients With Early-Stage Diabetic Kidney Disease.
    Tokita J; Lam D; Vega A; Wang S; Amoruso L; Muller T; Naik N; Rathi S; Martin S; Zabetian A; Liu C; Sinfield C; McNicholas T; Fleming F; Coca SG; Nadkarni GN; Tun R; Kattan M; Donovan MJ; Rahim AK
    J Prim Care Community Health; 2024; 15():21501319231223437. PubMed ID: 38185870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sodium glucose cotransporter 2 inhibitors plus standard care in diabetic kidney disease: A systematic review and meta-analysis.
    Woodhams LM; Chalmers L; Sim TF; Yeap BB; Schlaich MP; Schultz C; Hillis GS
    J Diabetes Complications; 2023 Jun; 37(6):108456. PubMed ID: 37127001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
    Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
    Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A qualitative study documenting unmet needs in the management of diabetic kidney disease (DKD) in the primary care setting.
    Datar M; Ramakrishnan S; Montgomery E; Coca SG; Vassalotti JA; Goss T
    BMC Public Health; 2021 May; 21(1):930. PubMed ID: 34001084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Payer budget impact of an artificial intelligence
    Datar M; Burchenal W; Donovan MJ; Coca SG; Wang E; Goss TF
    J Med Econ; 2021; 24(1):972-982. PubMed ID: 34304681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of diabetic kidney disease. A network meta-analysis.
    Büttner F; Barbosa CV; Lang H; Tian Z; Melk A; Schmidt BMW
    PLoS One; 2023; 18(11):e0293183. PubMed ID: 37917640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the identification and management of diabetic nephropathy in patients with diabetes in primary care.
    Picow E
    J Am Assoc Nurse Pract; 2023 Nov; 35(11):740-746. PubMed ID: 37471566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Derivation and independent validation of kidneyintelX.dkd: A prognostic test for the assessment of diabetic kidney disease progression.
    Nadkarni GN; Stapleton S; Takale D; Edwards K; Moran K; Mosoyan G; Hansen MK; Donovan MJ; Heerspink HJL; Fleming F; Coca SG
    Diabetes Obes Metab; 2023 Dec; 25(12):3779-3787. PubMed ID: 37722962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated glomerular filtration rate progression in UK primary care patients with type 2 diabetes and diabetic kidney disease: a retrospective cohort study.
    Cid Ruzafa J; Paczkowski R; Boye KS; Di Tanna GL; Sheetz MJ; Donaldson R; Breyer MD; Neasham D; Voelker JR
    Int J Clin Pract; 2015 Aug; 69(8):871-82. PubMed ID: 26011029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
    Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.
    Chan L; Nadkarni GN; Fleming F; McCullough JR; Connolly P; Mosoyan G; El Salem F; Kattan MW; Vassalotti JA; Murphy B; Donovan MJ; Coca SG; Damrauer SM
    Diabetologia; 2021 Jul; 64(7):1504-1515. PubMed ID: 33797560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
    Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
    Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ACE Inhibitors and Angiotensin Receptor Blockers in Normotensive Patients with Diabetic Kidney Disease.
    He D; Zhang Y; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Horm Metab Res; 2020 May; 52(5):289-297. PubMed ID: 32219798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors in non-diabetic kidney disease.
    Tesař V
    Adv Clin Exp Med; 2022 Feb; 31(2):105-107. PubMed ID: 35077036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.